Literature DB >> 11269921

Cotransmission from sympathetic vasoconstrictor neurons: differences in guinea-pig mesenteric artery and vein.

L Smyth1, J Bobalova, S M Ward, K D Keef, V N Mutafova-Yambolieva.   

Abstract

Vasoconstrictor responses to electrical field stimulation (EFS, 0.2-32 Hz, 0.1 ms, 12 V, for 1 min) were measured in endothelium-denuded segments of guinea-pig mesenteric vein and compared to responses in mesenteric artery. The distribution of both tyrosine-hydroxylase-like immunoreactivity (TH-LI) and neuropeptide Y-like immunoreactivity (NPY-LI) was also studied using anti-TH and anti-NPY antibodies. The effect of exogenous NPY (10 nM) on EFS (8 Hz, 0.3 ms, 12 V, for 1 min)-evoked overflow of noradrenaline (NA) was also studied using an HPLC technique with electrochemical detection. Veins responded with contractions at lower frequencies of stimulation than arteries. Prazosin (0.1 microM) abolished the EFS-evoked contractions in artery at 0.5-32 Hz and in vein at 0.2-1 Hz of stimulation. However, in vein, the contractile responses to EFS at 2-32 Hz of stimulation were only reduced by prazosin. Phentolamine (1 microM) abolished the responses to 0.5-4 Hz and reduced the responses to 8-32 Hz of EFS in artery. In vein, phentolamine (1 microM) abolished the responses to 0.2-1 Hz and facilitated the contractions elicited by 16-32 Hz. The NPY-receptor antagonist BIBP3226 (1 microM), in combination with phentolamine, abolished contractions in vein. Yohimbine (0.1 microM) abolished the responses to lower frequencies of stimulation in both artery (0.5-2 Hz) and vein (0.2-1 Hz). The responses to greater frequency stimulation were not affected by yohimbine in artery, and were facilitated in vein. Pre-treatment of animals for 24 h with reserpine abolished contractile responses to EFS in artery, whereas in vein, responses to 0.2-2 Hz were abolished while responses to 4-32 Hz were unchanged. Suramin (100 microM) or alpha,beta-methylene ATP (alpha,beta MeATP; 10-100 microM) treatment did not affect the contractile responses to EFS in either artery or vein. Pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid tetrasodium (PPADS; 30 microM), even potentiated the responses to 2-16 Hz in vein. However, following resperine-treatment, both PPADS and suramin reduced the nerve-evoked contractions of vein. Either BIBP3226 (1 microM) alone or BIBP3226 in combination with PPADS or suramin abolished the contractile response to EFS in reserpine-treated veins. NPY (100 nM) produced significantly more contraction in vein than in artery (i.e., 93 +/- 2.5 versus 7 +/- 4% of the response to 70 mM KCl, respectively). NPY (10 nM) significantly reduced the NA overflow evoked by EFS at 8 Hz. Flat mount preparations and cryostat sections of both mesenteric artery and vein revealed that TH-LI and NPY-LI were co-localized in a dense network of fibers within the adventitial layer. In conclusion, NA exclusively mediates the contractile response to sympathetic nerve stimulation in guinea-pig mesenteric artery, whereas at least three neurotransmitters [i.e., NA, adenosine 5'-triphosphate (ATP) and NPY] are involved in the neural response of mesenteric vein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11269921     DOI: 10.1016/S1566-0702(00)00203-4

Source DB:  PubMed          Journal:  Auton Neurosci        ISSN: 1566-0702            Impact factor:   3.145


  11 in total

1.  Modulation of sympathetic neurotransmission by neuropeptide Y Y2 receptors in rats and guinea pigs.

Authors:  Erica K Potter; Diana Tripovic
Journal:  Exp Brain Res       Date:  2006-05-30       Impact factor: 1.972

2.  Interaction between alpha(1)- and alpha(2)-adrenoreceptors contributes to enhanced constrictor effects of norepinephrine in mesenteric veins compared to arteries.

Authors:  Alexandra Sporkova; Alex Perez-Rivera; James J Galligan
Journal:  Eur J Pharmacol       Date:  2010-06-21       Impact factor: 4.432

3.  Differences in sympathetic neuroeffector transmission to rat mesenteric arteries and veins as probed by in vitro continuous amperometry and video imaging.

Authors:  Jinwoo Park; James J Galligan; Gregory D Fink; Greg M Swain
Journal:  J Physiol       Date:  2007-08-30       Impact factor: 5.182

4.  N-type and P/Q-type calcium channels regulate differentially the release of noradrenaline, ATP and beta-NAD in blood vessels.

Authors:  Lisa M Smyth; Ilia A Yamboliev; Violeta N Mutafova-Yambolieva
Journal:  Neuropharmacology       Date:  2008-09-25       Impact factor: 5.250

5.  P2X purinoceptors mediate an endothelium-dependent hyperpolarization in longitudinal smooth muscle of anterior mesenteric artery in young chickens.

Authors:  F Alkayed; A Boudaka; T Shiina; T Takewaki; Y Shimizu
Journal:  Br J Pharmacol       Date:  2009-08-19       Impact factor: 8.739

6.  Development of longitudinal smooth muscle in the posterior mesenteric artery and purinergic regulation of its contractile responses in chickens.

Authors:  Takahiko Shiina; Masato Koga; Shouichiro Saito; Yasuro Atoji; Tadashi Takewaki; Yasutake Shimizu
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2013-08-21       Impact factor: 1.836

7.  Purinergic receptors in the splanchnic circulation.

Authors:  Manuela Morato; Teresa Sousa; António Albino-Teixeira
Journal:  Purinergic Signal       Date:  2008-04-29       Impact factor: 3.765

8.  Alterations in sympathetic neuroeffector transmission to mesenteric arteries but not veins in DOCA-salt hypertension.

Authors:  Jinwoo Park; James J Galligan; Gregory D Fink; Greg M Swain
Journal:  Auton Neurosci       Date:  2009-11-13       Impact factor: 3.145

Review 9.  The purinergic neurotransmitter revisited: a single substance or multiple players?

Authors:  Violeta N Mutafova-Yambolieva; Leonie Durnin
Journal:  Pharmacol Ther       Date:  2014-06-02       Impact factor: 12.310

10.  Canine mesenteric artery and vein convey no difference in the content of major contractile proteins.

Authors:  Ilia A Yamboliev; Sean M Ward; Violeta N Mutafova-Yambolieva
Journal:  BMC Physiol       Date:  2002-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.